383.05 -15.95 (-4.00%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
379.5
Today’s High
405.55
52 Week Low
348.9
52 Week High
512.7
381.25 -17.60 (-4.41%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
379.75
Today’s High
405.75
52 Week Low
348.5
52 Week High
505.5
Key Metrics
- Market Cap (In Cr) 11254.28
- Beta 1.09
- Div. Yield (%) 0.63
- P/B 1.24
- TTM P/E 13.21
- Peg Ratio 0.57
- Sector P/E 28.26
- D/E 0.44
- Open Price 399.05
- Prev Close 399
Analysis
Price Analysis
-
1 Week-4.84%
-
3 Months-0.68%
-
6 Month5.96%
-
YTD-5.96%
-
1 Year-17.94%
Risk Meter
- 29% Low risk
- 29% Moderate risk
- 29% Balanced Risk
- 29% High risk
- 29% Extreme risk
Recos
17 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 1
- Hold
- 6
- Buy
- 8
- Strong Buy
- 2
Glenmark Pharmaceuticals News
Why pharma stocks are gaining despite fall in market; 3 stocks to buy today
2 min read . 23 Dec 2022
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 12304.9
- Selling/ General/ Admin Expenses Total
- 3374.22
- Depreciation/ Amortization
- 486.72
- Other Operating Expenses Total
- 1625.11
- Total Operating Expense
- 10725.77
- Operating Income
- 1579.14
- Net Income Before Taxes
- 1441.25
- Net Income
- 941.71
- Diluted Normalized EPS
- 39.91
- Period
- 2022
- Total Assets
- 17083.29
- Total Liabilities
- 7996.64
- Total Equity
- 9086.65
- Tangible Book Valueper Share Common Eq
- 241.04
- Period
- 2022
- Cashfrom Operating Activities
- 1108.65
- Cashfrom Investing Activities
- -333.28
- Cashfrom Financing Activities
- -520.49
- Net Changein Cash
- 272.43
- Period
- 2021
- Total Revenue
- 10943.93
- Selling/ General/ Admin Expenses Total
- 3242.35
- Depreciation/ Amortization
- 443.55
- Other Operating Expenses Total
- 1290.01
- Total Operating Expense
- 9258.56
- Operating Income
- 1685.37
- Net Income Before Taxes
- 1382.48
- Net Income
- 970.09
- Diluted Normalized EPS
- 33.26
- Period
- 2021
- Total Assets
- 15603.58
- Total Liabilities
- 8538.95
- Total Equity
- 7064.63
- Tangible Book Valueper Share Common Eq
- 167.62
- Period
- 2021
- Cashfrom Operating Activities
- 1131.21
- Cashfrom Investing Activities
- -675.24
- Cashfrom Financing Activities
- -441.78
- Net Changein Cash
- 27.82
- Period
- 2020
- Total Revenue
- 10640.97
- Selling/ General/ Admin Expenses Total
- 3254.42
- Depreciation/ Amortization
- 417.17
- Other Operating Expenses Total
- 1478.54
- Total Operating Expense
- 9326
- Operating Income
- 1314.96
- Net Income Before Taxes
- 1096.08
- Net Income
- 775.97
- Diluted Normalized EPS
- 26.7
- Period
- 2020
- Total Assets
- 14684.81
- Total Liabilities
- 8614.3
- Total Equity
- 6070.5
- Tangible Book Valueper Share Common Eq
- 137.8
- Period
- 2020
- Cashfrom Operating Activities
- 1392.41
- Cashfrom Investing Activities
- -783.52
- Cashfrom Financing Activities
- -444.66
- Net Changein Cash
- 174
- Period
- 2019
- Total Revenue
- 9865.47
- Selling/ General/ Admin Expenses Total
- 3188.08
- Depreciation/ Amortization
- 325.91
- Other Operating Expenses Total
- 1162.3
- Total Operating Expense
- 8438.39
- Operating Income
- 1427.08
- Net Income Before Taxes
- 1300.63
- Net Income
- 924.99
- Diluted Normalized EPS
- 28.55
- Period
- 2019
- Total Assets
- 13295.65
- Total Liabilities
- 7690.46
- Total Equity
- 5605.18
- Tangible Book Valueper Share Common Eq
- 137.09
- Period
- 2019
- Cashfrom Operating Activities
- 1324.17
- Cashfrom Investing Activities
- -698.99
- Cashfrom Financing Activities
- -738.74
- Net Changein Cash
- -297.08
- Period
- 2018
- Total Revenue
- 9103.07
- Selling/ General/ Admin Expenses Total
- 3624.5
- Depreciation/ Amortization
- 354.07
- Other Operating Expenses Total
- 309.1
- Total Operating Expense
- 7842.11
- Operating Income
- 1260.96
- Net Income Before Taxes
- 1066.8
- Net Income
- 774.19
- Diluted Normalized EPS
- 27.5
- Period
- 2018
- Total Assets
- 13020.96
- Total Liabilities
- 7431.9
- Total Equity
- 5589.05
- Tangible Book Valueper Share Common Eq
- 144.55
- Period
- 2018
- Cashfrom Operating Activities
- 1648.05
- Cashfrom Investing Activities
- -1013.34
- Cashfrom Financing Activities
- -468.5
- Net Changein Cash
- 176.99
- Period
- 2017
- Total Revenue
- 9185.68
- Selling/ General/ Admin Expenses Total
- 3541.2
- Depreciation/ Amortization
- 576.52
- Other Operating Expenses Total
- 586.16
- Total Operating Expense
- 7725.5
- Operating Income
- 1460.18
- Net Income Before Taxes
- 1260.15
- Net Income
- 915.97
- Diluted Normalized EPS
- 32.45
- Period
- 2017
- Total Assets
- 12211.97
- Total Liabilities
- 7272.54
- Total Equity
- 4939.43
- Tangible Book Valueper Share Common Eq
- 127.79
- Period
- 2017
- Cashfrom Operating Activities
- 657.43
- Cashfrom Investing Activities
- -712.34
- Cashfrom Financing Activities
- 543.15
- Net Changein Cash
- 199.24
- Period
- 2022-09-30
- Total Revenue
- 3375.25
- Selling/ General/ Admin Expenses Total
- 731.01
- Depreciation/ Amortization
- 155.71
- Other Operating Expenses Total
- 855.95
- Total Operating Expense
- 2909.39
- Operating Income
- 465.86
- Net Income Before Taxes
- 480.21
- Net Income
- 260.44
- Diluted Normalized EPS
- 9.23
- Period
- 2022-09-30
- Total Assets
- 18030.85
- Total Liabilities
- 8457.76
- Total Equity
- 9573.09
- Tangible Book Valueper Share Common Eq
- 253.56
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 201.87
- Cashfrom Investing Activities
- -306.04
- Cashfrom Financing Activities
- -98.9
- Net Changein Cash
- -171.48
- Period
- 2022-06-30
- Total Revenue
- 2777.29
- Selling/ General/ Admin Expenses Total
- 636.37
- Depreciation/ Amortization
- 146.76
- Other Operating Expenses Total
- 697.28
- Total Operating Expense
- 2492.44
- Operating Income
- 284.85
- Net Income Before Taxes
- 408.01
- Net Income
- 192.53
- Diluted Normalized EPS
- 6.82
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 3019.15
- Selling/ General/ Admin Expenses Total
- 577.68
- Depreciation/ Amortization
- 131.52
- Other Operating Expenses Total
- 947.2
- Total Operating Expense
- 2769.8
- Operating Income
- 249.34
- Net Income Before Taxes
- 269.69
- Net Income
- 155.58
- Diluted Normalized EPS
- 7.39
- Period
- 2022-03-31
- Total Assets
- 17083.29
- Total Liabilities
- 7996.64
- Total Equity
- 9086.65
- Tangible Book Valueper Share Common Eq
- 241.04
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 1108.65
- Cashfrom Investing Activities
- -333.28
- Cashfrom Financing Activities
- -520.49
- Net Changein Cash
- 272.43
- Period
- 2021-12-31
- Total Revenue
- 3173.41
- Selling/ General/ Admin Expenses Total
- 585.99
- Depreciation/ Amortization
- 118.93
- Other Operating Expenses Total
- 822.38
- Total Operating Expense
- 2777.57
- Operating Income
- 395.84
- Net Income Before Taxes
- 343.04
- Net Income
- 221.9
- Diluted Normalized EPS
- 12.28
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 3147.45
- Selling/ General/ Admin Expenses Total
- 687.33
- Depreciation/ Amortization
- 123.19
- Other Operating Expenses Total
- 726.4
- Total Operating Expense
- 2680.47
- Operating Income
- 466.98
- Net Income Before Taxes
- 384.96
- Net Income
- 257.66
- Diluted Normalized EPS
- 9.13
- Period
- 2021-09-30
- Total Assets
- 16613.46
- Total Liabilities
- 7952.23
- Total Equity
- 8661.23
- Tangible Book Valueper Share Common Eq
- 221.96
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 541.67
- Cashfrom Investing Activities
- 69.12
- Cashfrom Financing Activities
- -325.96
- Net Changein Cash
- 290.64
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day413.93
- 10 Day416.8
- 20 Day422.14
- 50 Day425.16
- 100 Day410.89
- 300 Day404.9
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sanofi India
- 5598.95
- -27.7
- -0.49
- 7404.27
- 5450
- 12958.99
- Suven Pharmaceuticals
- 489.75
- 0.75
- 0.15
- 623.51
- 387.5
- 12455.86
- Glenmark Pharmaceuticals
- 383.05
- -15.95
- -4
- 512.7
- 348.9
- 11254.28
- Alembic Pharmaceuticals
- 539.5
- -6.45
- -1.18
- 792.3
- 532.7
- 10732.35
- Natco Pharma
- 537.85
- 9.45
- 1.79
- 936.5
- 526
- 9643.58
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sanofi India
- 22.65
- 5.82
- 23.41
- 17.92
- Suven Pharmaceuticals
- 27.44
- 8.16
- -
- -
- Glenmark Pharmaceuticals
- 9.99
- 1.24
- 14
- 8.4
- Alembic Pharmaceuticals
- 20.62
- 2.05
- 20.8
- 15.4
- Natco Pharma
- 71.86
- 2.26
- 13.85
- 23.59
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 53.35%
- 150,550,469
- HSBC POOLED INVESTMENT FUND - HSBC POOLED ASIA PAC
- 3.48%
- 9,827,221
- ELLIPSIS PARTNERS LLC
- 1.68%
- 4,750,000
- HSBC GLOBAL INVESTMENT FUNDS - ASIA EX JAPAN EQUIT
- 1.04%
- 2,948,112
- Others
- 14.2%
- 40,047,086
- Others
- 11.78%
- 33,235,052
- HDFC LARGE AND MID CAP FUND
- 2.37%
- 6,688,650
- ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C
- 2.27%
- 6,410,385
- Others
- 0.99%
- 2,821,753
- ASHISH DHAWAN
- 2.48%
- 7,000,540
- Others
- 2.46%
- 6,936,923
- LIFE INSURANCE CORPORATION OF INDIA
- 2.93%
- 8,277,813
- Others
- 1.55%
- 4,365,886
- NTASAIN DISCOVERY MASTER FUND
- 2.34%
- 6,600,000
- Others
- 0.45%
- 1,277,304
- Others
- 1.26%
- 3,544,092
- Others
- 0.92%
- 2,591,938
- HUF
- 0.35%
- 976,540
- Clearing Members
- 0.05%
- 139,246
- Trusts
- 0.02%
- 58,746
- Bodies Corporate
- 0%
- 10
- Others
- 0.37%
- 1,030,500
- Others
- 0.2%
- 569,188
- Others
- 0.09%
- 241,492
- Others
- 0.04%
- 107,037
- Others
- 0.03%
- 72,058
- Others
- 0.01%
- 23,560
- Others
- 0%
- 8,737
- Others
- 0%
- 600
- Promoter & Promoter Group Shareholding
- 46.65%
- 131,617,687
- SALDANHA FAMILY TRUST
- 45.45%
- 128,241,936
- BLANCHE ELIZABETH SALDANHA
- 0.39%
- 1,110,327
- GLENN MARIO SALDANHA
- 0.35%
- 983,439
- CHERYLANN MARIA PINTO
- 0.27%
- 758,485
- ROBIN JOSEPH PINTO
- 0.18%
- 497,500
- NEHA SALDANHA
- 0.01%
- 26,000
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 10-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- 27-May-22
- Audited Results & Final Dividend
- 11-Feb-22
- Quarterly Results
- 12-Nov-21
- Quarterly Results
- 13-Aug-21
- Quarterly Results
- 28-May-21
- Audited Results & Final Dividend
- 12-Feb-21
- Quarterly Results & Others
- Meeting Date
- Announced on
- Purpose
- 16-May-22
- 13-Apr-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-May-22
- -
- 12-Sept-22
- 2.5
- 28-May-21
- -
- 08-Sept-21
- 2.5
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Glenmark Pharmaceuticals
- Industry Biotechnology & Drugs
- ISIN INE935A01035
- BSE Code 532296
- NSE Code GLENMARK
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.
MANAGEMENT
- Glenn Saldanha Executive Chairman of the Board, Chief Executive Officer, Managing Director
- V. S. Mani Global Chief Financial Officer, Executive Director
- Harish Kuber Compliance Officer, Company Secretary
- Cherylann Pinto Executive Director - Corporate Services
Company Summary
GLENMARK PHARMACEUTICALS SUMMARY
Glenmark Pharmaceuticals is trading 4.00% lower at Rs 383.05 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 405.55 & 379.5. Glenmark Pharmaceuticals has given -5.96% in this year & -4.84% in the last 5 days.
Glenmark Pharmaceuticals has TTM P/E ratio 13.21 as compared to the sector P/E of 28.26. There are 17 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 2 analysts who have given it a strong buy rating & 8 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.
The company posted a net profit of 260.44 Crores in its last quarter.
Listed peers of Glenmark Pharmaceuticals include Sanofi India (-0.49%), Suven Pharmaceuticals (0.15%), Glenmark Pharmaceuticals (-4%) etc.
Glenmark Pharmaceuticals has a 46.65% promoter holding & 53.35% public holding.
FAQs about Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is trading at 383.05 as on 27 Jan, 2023 3:29:54 PM. This is -4.00% lower as compared to its previous closing price of 399
The market capitalization of Glenmark Pharmaceuticals is 11254.28 Cr as on 27 Jan, 2023 3:29:54 PM.
The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 1 analysts have given a sell rating
- 6 analysts have given a hold rating
- 8 analysts have given a buy rating
- 2 analysts have given a strong buy rating
The 52 wk high for Glenmark Pharmaceuticals is 512.7 whereas the 52 wk low is 348.9
Glenmark Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 13.21
- Sector P/E: 28.26
- Dividend Yield: 0.63%
- D/E ratio: -
Glenmark Pharmaceuticals reported a net profit of 941.71 Cr in 2022.
